Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, aged 18 years and older~* Chronic phase, Philadelphia Chromosome-positive chronic myeloid leukemia (CML)~* Eastern Cooperative Oncology Group Performance Status score of 0-2~Key Exclusion Criteria:~* Pleural Effusion~* Uncontrolled cardiovascular disease~* Significant bleeding disorder unrelated to CML~* Prior treatment with interferon/imatinib/dasatinib/anti-CML systemic treatments except anagrelide/hydroxyurea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dasatinib (Type: EXPERIMENTAL): None
- Imatinib (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).